C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer

  • Authors:
    • Angela F. Logullo
    • Andreia B.G. Lopes
    • Suely Nonogaki
    • Fernando A. Soares
    • Mario Mourão Netto
    • Inês N. Nishimoto
    • M. Mitzi Brentani
  • View Affiliations

  • Published online on: July 1, 2007     https://doi.org/10.3892/or.18.1.121
  • Pages:121-126
Metrics: HTML 0 views | PDF 0 views
0

Abstract

The definition of high risk patients with early stage breast cancer is still controversial. We evaluated the ability of galectin-3, c-erbB-2 and p53 immunohistochemical expression to predict recurrence and survival in a homogeneous set of 92 patients with T1N0M0 ductal carcinoma with a long-term follow-up. In normal breast tissue, the epithelial and fibroblast components were positive for galectin-3 mostly showing nuclear and cytoplasmic reactivity. At the tumor epithelial component, galectin-3 expression was found in 46.7% of the samples with a predominant cytoplasmic staining. Similar results were presented by concurrent in situ lesions. Tumor stromal fibroblasts maintained positivity in 70 out of 92 cases (76%). We found expression of p53 in only 16 cases (17.4%), and c-erbB-2 in 17 (18.48%). A marginal association was found between co-expression of p53 and galectin-3 (p=0.055) and a significant correlation between p53 accumulation and c-erbB-2 expression (p=0.009). There was no significant association between galectin-3 protein expression with disease-free survival or overall survival. C-erbB2 and p53 expression correlated with recurrence (p=0.002, p=0.02; respectively). Diminished overall survival at 10 years was associated with c-erbB-2 (p=0.010), but marginally with p53 expression (p=0.076). Epithelial galectin-3 expression cannot be considered a prognostic factor for patients with T1N0M0 breast cancer, p53 seems to be of minor relevance and c-erbB-2 expression was the best discriminator and may be a marker for aggressive clinical behavior in patients with early stage breast cancer.

Related Articles

Journal Cover

July 2007
Volume 18 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

2016 Impact Factor: 2.662
Ranked #31/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Logullo, A.F., Lopes, A.B., Nonogaki, S., Soares, F.A., Netto, M.M., Nishimoto, I.N., & Brentani, M.M. (2007). C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer. Oncology Reports, 18, 121-126. https://doi.org/10.3892/or.18.1.121
MLA
Logullo, A. F., Lopes, A. B., Nonogaki, S., Soares, F. A., Netto, M. M., Nishimoto, I. N., Brentani, M. M."C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer". Oncology Reports 18.1 (2007): 121-126.
Chicago
Logullo, A. F., Lopes, A. B., Nonogaki, S., Soares, F. A., Netto, M. M., Nishimoto, I. N., Brentani, M. M."C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer". Oncology Reports 18, no. 1 (2007): 121-126. https://doi.org/10.3892/or.18.1.121